Exane Derivatives Sol Gel Technologies Ltd. Transaction History
Exane Derivatives
- $157 Million
- Q2 2022
A detailed history of Exane Derivatives transactions in Sol Gel Technologies Ltd. stock. As of the latest transaction made, Exane Derivatives holds 61 shares of SLGL stock, worth $930. This represents 0.0% of its overall portfolio holdings.
Number of Shares
61
Previous 61
-0.0%
Holding current value
$930
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding SLGL
# of Institutions
6Shares Held
388KCall Options Held
0Put Options Held
0-
Phoenix Holdings Ltd. Givatayim, L3247KShares$3.77 Million0.02% of portfolio
-
Raymond James Financial Services Advisors, Inc. St. Petersburg, FL88.5KShares$1.35 Million0.0% of portfolio
-
Raymond James & Associates St Petersburg, FL31.6KShares$482,2500.0% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L317.8KShares$270,7330.02% of portfolio
-
Black Rock Inc. New York, NY3.09KShares$47,1070.0% of portfolio
About Sol-Gel Technologies Ltd.
- Ticker SLGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 23,129,500
- Market Cap $353M
- Description
- Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...